Heavy Cannabis Users Have Lower Dopamine Release in Brain


Photo: Molecular Psychiatry

New York, NY, April 14, 2016—In a recent study, researchers found evidence of a compromised dopamine system in heavy users of marijuana. Lower dopamine release was found in the striatum--a region of the brain that is involved in working memory, impulsive behavior, and attention. Previous studies have shown that addiction to other drugs of abuse, such as cocaine and heroin, have similar effects on dopamine release, but such evidence for cannabis was missing until now.

“In light of the more widespread acceptance and use of marijuana, especially by young people, we believe it is important to look more closely at the potentially addictive effects of cannabis on key regions of the brain,” said Anissa Abi-Dargham, MD, professor of psychiatry (in radiology) at Columbia University Medical Center (CUMC) and a lead author of the paper.

The study included 11 adults between the ages of 21 and 40 who were severely dependent on cannabis and 12 matched healthy controls. On average, the cannabis group started using at age 16, became dependent on cannabis by age 20, and have been dependent for the past 7 years. In the month prior to the study, nearly all users in this study smoked marijuana daily.

Using positron emission tomography (PET) to track a radiolabelled molecule that binds to dopamine receptors in the brain, the scientists measured dopamine release in the striatum and its subregions, as well as in several brain regions outside the striatum, including the thalamus, midbrain, and globus pallidus. The cannabis users in this study stayed in the hospital for a week of abstinence to ensure that the PET scans were not measuring the acute effects of the drug. Participants were scanned before and after being given oral amphetamine to elicit dopamine release. The percent change in the binding of the radiotracer was taken as an indicator of capacity for dopamine release.

Compared with the controls, the cannabis users had significantly lower dopamine release in the striatum, including subregions involved in associative and sensorimotor learning, and in the globus pallidus.

The investigators also explored the relationship between dopamine release in a key area of the striatum and cognitive performance on learning and working memory tasks.  Although there was no difference between groups in task performance, in all participants lower dopamine release was associated with worse performance on both tasks.

“We don’t know whether decreased dopamine was a preexisting condition or the result of heavy cannabis use,” said Dr. Abi-Dargham. “But the bottom line is that long-term, heavy cannabis use may impair the dopaminergic system, which could have a variety of negative effects on learning and behavior.”

Jeffrey Lieberman, MD, chair of psychiatry at CUMC and past president of the American Psychiatric Association, noted that “these findings add to the growing body of research demonstrating the potentially adverse effects of cannabis, particularly in youth, at the same time that government policies and laws are increasing access and use.”




Deficits in striatal dopamine release in cannabis dependence” was published online on March 22, 2016, in Molecular Psychiatry. Authors are Elsmarieke van de Giessen, MD, PhD, Jodi J. Weinstein, MD, Clifford M. Cassidy, PhD, Margaret Haney, PhD, Zhengchao Dong, PhD, Rassil Ghazzaoui, MA, Najate Ojeil, MA, Lawrence S. Kegeles, MD, PhD, Xiaoyan Xu, PhD, Nehal P. Vadhan, PhD, Nora D. Volkow, MD, Mark Slifstein, PhD, and Anissa Abi-Dargham, MD.  Affiliations are: Department of Psychiatry, Columbia University Medical Center and New York State Psychiatric Institute, New York NY (EvdG, JJW, CMC, MH, ZD, RG, NO, LSK, XX, NPV, MS, AA); Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands (EvdG); Department of Psychiatry, Stony Brook University School of Medicine, New York, NY (NPV); National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, (NV).

Dr. Haney has received partial salary support for investigator-initiated studies from Insys Therapeutics Inc and Lifeloc Technologies and has served as a consultant to Aelis Farma and Health Advances LLC. Dr. Kegeles has received research support from Amgen. Dr. Slifstein has received research support from Forest Laboratories, PierreFabre, CHDI, and Otsuka and has provided consultation for Amgen. Dr. Abi-Dargham has received research support from Takeda and Forest Pharmaceuticals and has served on advisory boards for Roche, Forum, and Otsuka. The remaining authors declare no conflict of interests.

Funding for this study was provided by grant R01 DA022455-01A1 from the National Institute on Drug Abuse to Dr. Abi-Dargham. Dr. van de Giessen was supported by a Rubicon grant from the Netherlands Organisation for Scientific Research (825.12.009).


Columbia University Department of Psychiatry

Columbia Psychiatry holds the top ranking among the psychiatry departments in the nation and has contributed greatly to the understanding and treatment of brain disorders. Co-located at the New York State Psychiatric Institute on the NewYork-Presbyterian Hospital/Columbia University Medical Center campus in Washington Heights, the department enjoys a rich and productive collaborative relationship with physicians in various disciplines at Columbia University’s College of Physicians and Surgeons. Columbia Psychiatry is home to distinguished clinicians and researchers noted for their clinical and research advances in the diagnosis and treatment of depression, suicide, schizophrenia, bipolar and anxiety disorders, eating disorders, substance use disorders, and childhood psychiatric disorders.

Columbia University Medical Center provides international leadership in basic, pre-clinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and state and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.